they have enrolled 205 patients until April 20.
75 from January 1st. or 22 per month. They still have 8 months to enroll or 8*22 = 176 patients
that this is very close to a total of 388.
In addition they are going to open new sites and the enrolling-rate can be increased
It's also true that a smaller number could be enough to reach the statistical significa for FDA approval.
Note: In Q1/16 is expected the FINAL results not an interim update.
All right , but we have to wait for something really big like partnership or EPIC results to see the dollars area.
Results and partnership will send us over $3 and if the partnership is in the cardiovascular sector much more.
you know my opinion is that the trial could be stopped early, opinion based on the previous results and on the greater number of patients.
Certainly they know that it is going well ,but maybe they want to proof the safety in multiple doses and they want reach a clear statistical significate also in adult arm, reasons to enroll all 388 patients.(It would be interesting toknow if adult sub set is included in this number)
As already calculed I think that they are enrolling about 20 pts per month (130 end of December - 205 April 20), if true Epic could finish this fall.
certainly they can have informations personally from Culley before to invest, IMO I think that they know exactly how the trials are going
just my opinion
- 2 drugs for big market in cardiovascular field
-1 drug in a easy P3 trial
-2 drug in P2
- stock very undervalued
- cash enough for 2025 and 2016
- but above all they know things that we ignore.
Sentiment: Strong Buy
Dr. R. Martin Emanuele, Senior Vice President, Development, said: "These results are encouraging since hemolysis and adhesiveness of sickle red blood cells are thought to be causal pathologies underlying vaso-occlusive crisis. Of note, we observed a strong concentration-related response for both parameters, which supports the veracity of the drug effect. Also, with regard to the inhibition of cell adhesion, the maximal response in this study was observed over the range of blood concentrations we are targeting in our ongoing Phase 3 study. As such, this data is supportive of effects we expect to see in our Phase 3 EPIC study."
It seems that all is going well, as expected.
Perhaps they are a few slow ,but I think to avoid possible mistakes